Didier Hoch - DBV Technologies Director

Director

Mr. Didier Hoch was a Director of DBV Technologies SA since June 6, 2012. He is the currently the Chairman of BioVision, an Independent board member of Effimune, Genticel and Pevion, and a Strategic advisor for companies involved in Life Sciences Health. He was a physician working for the Pharmaceutical and Vaccine industry for 25 years. He was notably Chairman of Sanofi Pasteur MSD from 2000 to 2010. Previously he was in charge of different functions in the pharmaceutical area within Rhone Poulenc Rorer, then Aventis Europe and Middle East Africa. Besides that, he is President of the Life Science Health Committee of the MEDEF . He was President, of the European Vaccine Manufacturers Association and President from 2006 to 2012 of the Biotechnology Committee of the French Pharma industry association . He graduated from University of Lyon with a Doctorate of Medicine degree in Medicine. since 2012.
Tenure 12 years
Phone33 1 55 42 78 78
Webhttps://www.dbv-technologies.com

DBV Technologies Management Efficiency

The company has return on total asset (ROA) of (31.96) % which means that it has lost $31.96 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (67.72) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 4.63 M in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. DBV Technologies has a current ratio of 3.4, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist DBV Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, DBV Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DBV Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DBV to invest in growth at high rates of return. When we think about DBV Technologies' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Mike OBrienRyanair Holdings PLC
73
Edward ShapiroUnited Airlines Holdings
53
William KacalUS Silica Holdings
72
Kyran McLaughlinRyanair Holdings PLC
73
Richard ZwernHawaiian Holdings
63
Samson PoomaihealaniHawaiian Holdings
72
Randall JensonHawaiian Holdings
49
Michael CawleyRyanair Holdings PLC
63
Louise PhelanRyanair Holdings PLC
50
Michael LawsonUS Silica Holdings
N/A
Renato SalomoneVolaris
N/A
Zac HirzelHawaiian Holdings
37
James OsborneRyanair Holdings PLC
67
Ricardo YanezVolaris
52
Edward PhilipUnited Airlines Holdings
53
Abhinav DharHawaiian Holdings
46
Charles YamaroneUnited Airlines Holdings
55
Crystal RoseHawaiian Holdings
60
Stan McCarthyRyanair Holdings PLC
59
Michael HorganRyanair Holdings PLC
77
Sito PantojaUnited Airlines Holdings
61
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. Dbv Technologies is traded on OTC Exchange in the United States. DBV Technologies SA [DBVTF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

DBV Technologies Leadership Team

Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Ehouarn, Industrial Development and Production Director
Claude Thebault, Medical Director
Wence Agbotounou, Chief Clinical Trial Officer
Laurent Martin, Director of Regulatory Affairs
Viviane Monges, Director
Didier Hoch, Director
Hugh Sampson, Chief Scientific Officer
Charles Ruban, Chief Development Officer
Nathalie Donne, Director of Bus. Devel. and Corporate Communication
Lucie Mondoulet, Director of Research Department
Chahra Louafi, Director - Representative of CDC Entreprises (Innobio)
Peter Hutt, Independent Director
Rafaele Tordjman, Director - Representative of Sofinnova Partners
Bertrand Dupont, Co-Founder and Sr. Executive VP of Technology
Veronique Foutel, Director of Strategic Marketing
FAAAAI MD, Chief Scientific Officer, Advisor and Member of The Scientific Advisory Board
Daniel Tasse, CEO, Director
Rafale Tordjman, Director - Representative of Sofinnova Partners
Joan Schmidt, Executive Vice President General Counsel
George Horner, Director
Torbjorn Bjerke, Independent Director
Pharis Mohideen, Chief Medical Officer
PierreHenri Benhamou, Chairman of the Board, CEO
Torbjrn Bjerke, Independent Director
Mailys Ferrere, Director
Michel Rosen, Director
David Schilansky, COO

DBV Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with DBV Technologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to DaVita HealthCare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DaVita HealthCare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DaVita HealthCare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DaVita HealthCare Partners to buy it.
The correlation of DaVita HealthCare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DaVita HealthCare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DaVita HealthCare moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DaVita HealthCare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Consideration for investing in DBV OTC Stock

If you are still planning to invest in DBV Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DBV Technologies' history and understand the potential risks before investing.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum